IXICO plc Result of General Meeting (5455P)
May 29 2018 - 6:08AM
UK Regulatory
TIDMIXI
RNS Number : 5455P
IXICO plc
29 May 2018
29 May 2018
IXICO plc
("IXICO" or the "Company")
Result of General Meeting
Further to the announcement on 3 May 2018 in relation to the
placing ("Placing") of new ordinary shares ("Placing Shares") in
the Company to raise GBP5.5 million and the despatch of a related
shareholder circular, IXICO plc (AIM: IXI), the digital
technologies company serving neuroscience, is pleased to announce
that all resolutions proposed at the General Meeting of the Company
held earlier today were duly passed.
Total voting rights
As a result, the Placing has become unconditional other than in
respect of admission of the Placing Shares to trading on AIM.
Application has been made for admission to trading on AIM of
19,642,856 Placing Shares. Admission of the Placing Shares on AIM
is expected to become effective at 8.00 a.m. on 30 May 2018,
following which there will be in total 46,761,986 ordinary shares
in the capital of the Company in issue, each carrying equal voting
rights.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in,
IXICO under the FCA's Disclosure and Transparency Rules.
For further information please contact:
IXICO plc Tel: +44 20 3763
Giulio Cerroni, Chief Executive 7499
Officer
Susan Lowther, Chief Financial
Officer
Shore Capital (Nomad and Broker) Tel: +44 20 7408
Edward Mansfield / Anita Ghanekar 4090
/ Daniel Bush
FTI Consulting Limited (Investor Tel: +44 20 3727
Relations) 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMLLFILEEIAFIT
(END) Dow Jones Newswires
May 29, 2018 07:08 ET (11:08 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024